Rani Abraham

Rani Abraham is a pharmacologist and AI driven clinical development strategist working at the intersection of pharmaceutical innovation, regulatory affairs and artificial intelligence. With extensive experience across Phase I–IV clinical trials, she brings together scientific expertise, regulatory insight, operational leadership and technology enablement to advance drug development.

Rani advises organizations on AI augmented clinical trials, integrated evidence generation, regulatory innovation and the adoption of AI enabled solutions across drug discovery, preclinical research and clinical development. Her work focuses on translating emerging technologies into practical, scalable applications that improve decision making and transform how clinical research is designed and delivered.

Her hands on experience includes developing AI enabled oncology precision medicine models and clinical decision support systems, supported by therapeutic expertise spanning oncology, immuno-oncology, rare diseases, metabolic disorders, cardiovascular disease and other therapeutic areas.

Rani also advises investment firms, legal practices and corporate strategy teams on the pharmaceutical and CRO sectors. She brings an informed perspective on clinical trial operations, the economics of AI enabled drug development and the distinction between proven capabilities and technologies that remain at the pilot stage. Drawing on more than 16 years of experience across clinical research, regulatory affairs and technology enablement, she translates complex scientific, regulatory and operational developments into commercially relevant insights that inform investment and strategic decisions.

She holds an M.Pharm specializing in immuno-oncology pharmacology from MAHE University, Manipal, India, and an MSc in Artificial Intelligence and its Applications from the University of Strathclyde, Glasgow, UK.